Attached files

file filename
EX-32.1 - EX-32.1 - Zynerba Pharmaceuticals, Inc.zyne-20180930ex321b8b198.htm
EX-31.2 - EX-31.2 - Zynerba Pharmaceuticals, Inc.zyne-20180930ex312c1b721.htm
EX-31.1 - EX-31.1 - Zynerba Pharmaceuticals, Inc.zyne-20180930ex3113f5d24.htm
10-Q - 10-Q - Zynerba Pharmaceuticals, Inc.zyne-20180930x10q.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Zynerba Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September  30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James E. Fickenscher, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ James E. Fickenscher

James E. Fickenscher

Chief Financial Officer 

Dated: November 8, 2018